Revenue grows 42% in Q1FY23. Pharma Revenue in Latin America up 39%. Profit After Tax up 32% YoY. Balaxi Pharmaceuticals...
balaxi
Revenue up 23%, Profit After Tax expands 29% Pharma income up 50% with increasing contribution from Latin America Balaxi Pharmaceuticals...
Revenue progress of 40.3% on YoY foundation, with working EBITDA of Rs. 15.29 crore PAT stood at Rs. 8.23 crore...
